• Bhoj Sakshi Suresh
• Waghmare A.D.
• Kolhe S.D.
• Hajare A.R.
• Handore P.D.

In Europe, Lenmeldy is also known as Libmeldy, where it has been approved by the European Commission (EC), UK Medicines and Healthcare products Regulatory Agency (MHRA) and Swiss Agency for Therapeutic Products. Lenmeldy is indicated for the treatment of children with pre- symptomatic late infantile (PSLI), pre-symptomatic early juvenile (PSEJ) or early symptomatic early juvenile (ESEJ) metachromatic leukodystrophy. Lenmeldy is a gene therapy used to treat types of metachromatic leukodystrophy in children. It is world’s new most expensive drug. Lenmeldy tablet is a mainly used in the treatment of neurological disorders, like epilepsy. It contains a combination of active ingredients designed to modulate neuronal activity and reduce seizure frequency in patients with refractory epilepsy. This is the first FDA-approved treatment option for children who have this rare genetic disease. -Proper Name: atidarsagene autotemcel -Trade Name: LENMELDY -Manufacture: Orchard Therapeutics (Europe) Limited

Lenmeldy, metachromatic leukodystrophy, epilepsy, gene therapy.

"A review and research on Lenmeldy", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.12, Issue 1, page no.f69-f79, January-2025, Available :http://www.jetir.org/papers/JETIR2501509.pdf

"A review and research on Lenmeldy", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.12, Issue 1, page no. ppf69-f79, January-2025, Available at : http://www.jetir.org/papers/JETIR2501509.pdf